C I Neutel1, W C Appel. 1. Bureau of Drug Surveillance, Therapeutic Products Programme, Health Canada, Ottawa, Ontario, Canada.
Abstract
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of gastrointestinal (GI) complications. Excessive alcohol consumption may further increase this risk and the FDA is requiring warnings on over-the-counter (OTC) NSAIDs. Our objective is to evaluate the risk of NSAID-related GI events for persons with a history of alcohol abuse. METHODS: This case control study used data from Saskatchewan Health. Cases consisted of 1083 patients hospitalized for severe GI events, whereas the control group consisted of 14,754 persons without such hospitalizations. RESULTS: Five percent of cases and 1.9% of controls had a history of treatment for alcohol abuse. The presence of either NSAID use or a history of alcohol abuse led to an odds ratio (OR) of 2.9* for severe GI events, whereas the presence of both risk factors simultaneously led to an OR of 10.2* (additive would be 5.8). Similarly, the presence of ibuprofen and naproxen use, which are OTC in the USA, without alcohol abuse led to an OR of 1.9*, whereas alcohol abuse by itself led to an OR of 2.4*. The presence of both OTC NSAIDs and alcohol abuse simultaneously, led to an OR of 6.5 (additive would be 4.3). Thus with both risk factors present, the resulting risk ratio is greater than the additive risk of the separate risk factors. CONCLUSIONS: The Food and Drug Administration (FDA) warning concerns concurrent use of alcohol with NSAIDs, whereas the present study presents the effect of long term alcohol abuse. Further research is needed to separate these two issues to allow physicians to provide the best advice to their patients. *Statistically significant at p<0.05.
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of gastrointestinal (GI) complications. Excessive alcohol consumption may further increase this risk and the FDA is requiring warnings on over-the-counter (OTC) NSAIDs. Our objective is to evaluate the risk of NSAID-related GI events for persons with a history of alcohol abuse. METHODS: This case control study used data from Saskatchewan Health. Cases consisted of 1083 patients hospitalized for severe GI events, whereas the control group consisted of 14,754 persons without such hospitalizations. RESULTS: Five percent of cases and 1.9% of controls had a history of treatment for alcohol abuse. The presence of either NSAID use or a history of alcohol abuse led to an odds ratio (OR) of 2.9* for severe GI events, whereas the presence of both risk factors simultaneously led to an OR of 10.2* (additive would be 5.8). Similarly, the presence of ibuprofen and naproxen use, which are OTC in the USA, without alcohol abuse led to an OR of 1.9*, whereas alcohol abuse by itself led to an OR of 2.4*. The presence of both OTC NSAIDs and alcohol abuse simultaneously, led to an OR of 6.5 (additive would be 4.3). Thus with both risk factors present, the resulting risk ratio is greater than the additive risk of the separate risk factors. CONCLUSIONS: The Food and Drug Administration (FDA) warning concerns concurrent use of alcohol with NSAIDs, whereas the present study presents the effect of long term alcohol abuse. Further research is needed to separate these two issues to allow physicians to provide the best advice to their patients. *Statistically significant at p<0.05.
Authors: Angela Christina Busch; Meenakshi Denduluri; Joseph Glass; Scott Hetzel; Shalu P Gugnani; Michele Gassman; Dean Krahn; Brienna Deyo; Randall Brown Journal: Alcohol Clin Exp Res Date: 2017-06-12 Impact factor: 3.455
Authors: Lene Mellemkjaer; William J Blot; Henrik Toft Sørensen; Lars Thomassen; Joseph K McLaughlin; Gunnar Lauge Nielsen; Jørgen H Olsen Journal: Br J Clin Pharmacol Date: 2002-02 Impact factor: 4.335
Authors: Laura Murphy; Karen Wk Ng; Victoria Ch Su; Sarah Woodworth-Giroux; Todd S Levy; Beth A Sproule; Andrea D Furlan Journal: J Pain Res Date: 2015-11-30 Impact factor: 3.133
Authors: Jeong-Oog Lee; Ji Hye Kim; Sunggyu Kim; Mi-Yeon Kim; Yo Han Hong; Han Gyung Kim; Jae Youl Cho Journal: J Ginseng Res Date: 2019-11-15 Impact factor: 6.060